895 results on '"Smyth, Susan"'
Search Results
202. Coronary Restenosis
203. Granule cargo release from bone marrow-derived cells sustains cardiac hypertrophy
204. Lipid phosphate phosphatases: more than one way to put the brakes on LPA signaling?
205. The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome
206. Phosphodiesterase Type 4 Blockade Prevents Platelet-Mediated Neutrophil Recruitment at the Site of Vascular Injury
207. A RETROSPECTIVE ANALYSIS OF CATHETER-BASED THROMBOLYSIS FOR TREATMENT OF PULMONARY EMBOLISM
208. Mice With Targeted Inactivation of Ppap2b in Endothelial and Hematopoietic Cells Display Enhanced Vascular Inflammation and Permeability
209. Arguing the Case for the Autotaxin–Lysophosphatidic Acid–Lipid Phosphate Phosphatase 3-Signaling Nexus in the Development and Complications of Atherosclerosis
210. Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
211. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes
212. Lipid Phosphate Phosphatases Regulate Lysophosphatidic Acid Production and Signaling in Platelets: STUDIES USING CHEMICAL INHIBITORS OF LIPID PHOSPHATE PHOSPHATASE ACTIVITY
213. Invasive Coronary Vasoreactivity Testing to Diagnose Microvascular Dysfunction in Women⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology
214. Novel mediators and biomarkers of thrombosis
215. Tiny dancers: the integrin–growth factor nexus in angiogenic signaling
216. Integrin‐mediated cell surface recruitment of autotaxin promotes persistent directional cell migration
217. Antiplatelet therapy in prevention of cardio- and venous thromboembolic events
218. Lipid Phosphate Phosphatase 3 as an Essential Regulator of Vascular Inflammation and Diabetic Restenosis
219. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway
220. Autotaxin Production of Lysophosphatidic Acid Mediates Allergic Asthmatic Inflammation
221. Mechanism of rapid elimination of lysophosphatidic acid and related lipids from the circulation of mice
222. Inflammation and thrombosis in cardiovascular disease
223. Targeting Platelet Thrombin Receptor Signaling to Prevent Thrombosis
224. Fibrinolytic Therapy Versus Primary Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction in Kentucky
225. Bioactive Lipids and Cationic Antimicrobial Peptides as New Potential Regulators for Trafficking of Bone Marrow-Derived Stem Cells in Patients with Acute Myocardial Infarction
226. Tissue necrosis factor α and targeting its receptor in ischaemic heart disease
227. Lysophosphatidic acid and cardiovascular disease: seeing is believing
228. Integrin αIIbβ3
229. Lysophosphatidic Acid (LPA) Signaling and Cardiovascular Pathology
230. Lipid Phosphate Phosphatase 3 Negatively Regulates Smooth Muscle Cell Phenotypic Modulation to Limit Intimal Hyperplasia
231. Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement.
232. Characterization of a Novel Integrin Binding Protein, VPS33B, Which Is Important for Platelet Activation and In Vivo Thrombosis and Hemostasis.
233. The P2Y12 Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y12/Gi-Dependent Mechanism
234. Platelets Protect From Lipopolysaccharide-Induced Lethal Endotoxemia by Inhibiting Macrophage-Dependent Inflammation Via the Cyclooxygenase 1 (COX1) Signaling Pathway
235. Novel Role for Bioactive Lipids in Mobilization of Bone Marrow Stem Cells During Myocardial Ischemia: Sphingosine-1 Phosphate (S1P) As Potential Therapeutic Target
236. Clopidogrel treatment and the incidence and severity of community acquired pneumonia in a cohort study and meta-analysis of antiplatelet therapy in pneumonia and critical illness
237. Coronary Artery Remodeling in a Model of Left Ventricular Pressure Overload Is Influenced by Platelets and Inflammatory Cells
238. Preventing Platelet Thrombosis With a PAR1 Pepducin
239. Spontaneous coronary thrombosis following thrombolytic therapy for acute cardiovascular accident and stroke: a case study
240. Nondestructive Testing of Ultrasonic Welding Joints Using Shearography Technique
241. Abstract 382: Mice with Endothelial-Targeted Inactivation of PPAP2B (Lipid Phosphate Phosphatase 3) Display Enhanced Vascular Inflammation and Permeability
242. Abstract 228: Secretion of Bone Marrow--Derived Cells Contributes to Pressure-Overload--Induced Left Ventricular Hypertrophy
243. Abstract 217: The P2Y12 Antagonists, 2MeSAMP and AR-C69931MX, Inhibit Platelet Activation Through the P2Y12/Gi-Dependent Mechanism
244. Autotaxin and Its Product Lysophosphatidic Acid Suppress Brown Adipose Differentiation and Promote Diet-Induced Obesity in Mice
245. Biomarker science: on a theme of personalized medicine
246. Platelet Biology and Response to Antiplatelet Therapy in Women
247. NOVEL ROLE FOR BIOACTIVE LIPIDS IN STEM CELL MOBILIZATION DURING MYOCARDIAL ISCHEMIA: A POTENTIAL THERAPEUTIC TARGET
248. PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL
249. INCREASED MORBIDITY AND MORTALITY AMONG ATRIAL FIBRILLATION PATIENTS WITH PROLONGED QRS: RESULTS FROM THE AFFIRM STUDY
250. Aim and scope of the fellows forum
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.